Niagen Bioscience swings to Q3 net loss of $1.17 million from year-earlier profit
Bitget2026/11/04 21:07- Niagen Bioscience swung to a third-quarter 2026 net loss of $1.17 million from a year-earlier profit.
- Net sales fell 20% year-over-year to $27.19 million.
- Quarterly operating cash flow totaled $2.6 million, while cash and cash equivalents ended the quarter at $69.5 million.
- New launches included ready-to-inject Niagen at-home injections and the Niagen NanoCloud topical skincare product.
- Management expects operating expenses to increase in 2026 to support strategic investments, with injectables and skincare partnerships becoming meaningful contributors in 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
